Cecilia Smith S.
- Country
- Norway
- Department
- Neurology department, Drammen Hospital
Research Overview
- Phase 3 Randomized Double‑Blind Study of Orelabrutinib vs Placebo on Disability Progression in Non‑Active Secondary Progressive Multiple Sclerosis
- A Multicenter Non-Inferiority Trial Comparing Rituximab and Ocrelizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis Aged 18-60 Years
- Evaluation of Tenofovir Alafenamide as an Adjunct to Anti-CD20 Therapy in Reducing Neuronal Damage in Multiple Sclerosis: A Phase 2b Randomized Controlled Trial
Data & Insights
Has run more than one trial at 4 of 118 partner sites.
Specializations
Neurological Disorders
This investigator specializes in treating and researching relapsing-remitting multiple sclerosis, with particular emphasis on innovative therapeutic approaches for managing MS symptoms and disease progression.
- Multiple Sclerosis Treatment Optimization
- Anti-CD20 Therapy Applications
- Combination Treatment Strategies
The investigator focuses on evaluating comparative effectiveness of different therapeutic agents in multiple sclerosis management.
Immunological Interventions
The investigator has demonstrated expertise in studying targeted immunotherapy approaches, particularly examining the clinical applications of monoclonal antibodies in neurological conditions.
- Biological Therapy Assessment
- Treatment Safety Profiles
- Add-on Therapy Evaluation
Their work encompasses the evaluation of novel therapeutic combinations and their safety implications in MS treatment.
Clinical Innovation
The investigator's research includes exploring advanced treatment protocols for active MS, with emphasis on developing effective therapeutic strategies for adult patients.
- Non-inferiority Studies
- Treatment Optimization
- Patient Safety Assessment
Their work contributes to expanding treatment options for patients with active relapsing forms of multiple sclerosis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.